Latest news
Business Update
Innosuisse-Funded Alzheimer’s Clinical Trial with MIAMIND®
The MIAMIND® electrical neurostimulator will be evaluated in a randomized, sham-controlled clinical trial in patients with early-stage Alzheimer’s disease (AD), supported by funding from Innosuisse.
08 April, 2026
Read more
Events & Conferences | Tue 03, 2022
Supporter at the Dementia Conference in Bern 2022
We are happy to announce that Bottneuro will participate as supporter at the Dementia Conference in Bern on April 28th, where diagnostics and early de
Business Update | Thu 03, 2022
Bottneuro moves to a new location
This February we were already able to move into our new office. it is still located on the Novartis Campus, but in a different building on the 12th fl
Business Update | Fri 12, 2021
Bottneuro wins CHF 150,000 to advance diagnosis and digital therapies for Alzheimer’s disease
Business Update | Mon 11, 2021
Switzerland advances personalized Alzheimer’s therapy
Tokyo (SCCIJ) – The two Swiss-based companies Positrigo and Bottneuro have joined forces to foster the early diagnosis and personalized treatment of A
Featured news
Bottneuro Team
Dr Antonella Santuccione Chadha joins the Board of Directors at Bottneuro
02 June, 2025
